Taken together, these findings suggesting that increased expression of miR‐641 significantly contributes to EGFR‐TKI resistance development and inhibition of miR‐641 may be a novel strategy for treatment of erlotinib‐resistant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.